#2626929
ag aithint go raibh dea-tionchar uilíoch ar an iomlán ag an tSaoráid um Rochtain Dhomhanda ar Vacsaín COVID-19 (COVAX), saoráid ar bhain roinnt dúshláin cur chun feidhme agus laigí di i rith an phróisis, agus á chur in iúl gur geal léi an dea-thionchar sin; ag tabhairt dá haire, faoi lár mhí an Mhárta 2022, go raibh os cionn 1,3 billiún dáileog curtha ar fáil ag COVAX do 144 thír agus gur saor in aisce a deonaíodh os cionn 500 milliún dáileog díobh sin; ag tabhairt dá haire, faoi lár mhí an Mhárta 2022, go raibh os cionn 400 milliún dáileog roinnte ag na Ballstáit; ag tabhairt dá haire gur chuir ganntanas soláthair bac ar thionchar COVAX, rud a d’fhág nárbh fhéidir le COVAX an sprioc a bhí aige le haghaidh 2021 a bhaint amach;
Acknowledges and welcomes the overall positive global impact of COVID-19 Vaccines Global Access (COVAX), which was marked by several implementation challenges and weaknesses throughout the process; notes that by mid-March 2022, COVAX had delivered over 1,3 billion doses to 144 countries, of which over 500 million doses were donations; notes that by mid-March 2022 the Members States had shared over 400 million doses; notes that the impact of COVAX has been hindered by supply shortages, which prevented COVAX from meeting its target for 2021;